Description

Agrel (clopidogrel) Coated Tablets 75 mg. №28

Ingredients

Active ingredient: Clopidogrel bisulfate 75 mg.
Other ingredients: Microcrystalline cellulose, lactose monohydrate, colloidal anhydrous silica, croscarmellose sodium, magnesium stearate, hypromellose, macrogol 6000, titanium dioxide (E171).

Dosage

Recommended dosage: 75 mg once daily, with or without food.
Do not exceed the prescribed dose without consulting a healthcare professional.

Indications

Agrel (clopidogrel) coated tablets are indicated for the prevention of atherothrombotic events in patients with a history of recent myocardial infarction, recent stroke, or established peripheral arterial disease.

Contraindications

Do not use Agrel (clopidogrel) coated tablets if you are allergic to clopidogrel or any other ingredients in the formulation.
Consult a healthcare provider before use if you have a history of bleeding disorders or ulcers.

Directions

Swallow the tablet whole with water.
Do not crush or chew the tablet.
Follow the dosage instructions provided by your healthcare provider.

Scientific Evidence

Clopidogrel, the active ingredient in Agrel tablets, is a platelet aggregation inhibitor that works by irreversibly binding to the P2Y12 ADP receptor on platelets, preventing platelet activation and aggregation. Clinical trials have shown clopidogrel to be effective in reducing the risk of cardiovascular events in high-risk patients. A study published in the New England Journal of Medicine demonstrated a significant reduction in the combined risk of myocardial infarction, stroke, or cardiovascular death with clopidogrel therapy.

Additional Information

It is important to inform your healthcare provider about all medications, including over-the-counter drugs and supplements, before starting Agrel (clopidogrel) therapy.
Store the tablets in a cool, dry place away from direct sunlight.
Keep out of reach of children.

Pharmacological Effects: Clopidogrel inhibits platelet aggregation by selectively and irreversibly binding to the P2Y12 ADP receptor on platelets. This action prevents ADP-mediated activation of the glycoprotein IIb/IIIa complex, thereby inhibiting platelet activation and subsequent aggregation.

Clinical Trials: Clinical trials have shown that clopidogrel, such as in Agrel tablets, is effective in reducing the risk of cardiovascular events in patients with a history of atherothrombotic events. A meta-analysis published in the Journal of the American College of Cardiology confirmed the efficacy of clopidogrel in reducing major cardiovascular events, including myocardial infarction and stroke, in high-risk patients.